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Simple Summary: As pancreatic cancer is a disease with a high fatality rate, a better understanding
of how it develops and the identification of new potential targets for its treatment are greatly needed.
In this current study, we showed that the expression of amyloid precursor-like protein 2 (APLP2) in
pancreatic cancer epithelial cells is higher than in precursor lesion epithelial cells, thus indicating that
APLP2 increases during human pancreatic cancer development. We also generated a new mouse
model that demonstrated the deletion of APLP2 expression specifically within the pancreas prolongs
survival and decreases metastasis for mice with pancreatic cancer. Taken together, these findings
open a new avenue toward comprehending and treating pancreatic cancer.
Abstract: In the United States, pancreatic cancer is a major cause of cancer-related deaths. Although
substantial efforts have been made to understand pancreatic cancer biology and improve therapeutic
efficacy, patients still face a bleak chance of survival. A greater understanding of pancreatic cancer
development and the identification of novel treatment targets are desperately needed. Our analysis
of gene expression data from patient samples showed an increase in amyloid precursor-like protein 2
(APLP2) expression within primary tumor epithelium relative to pancreatic intraepithelial neoplasia
(PanIN) epithelial cells. Augmented expression of APLP2 in primary tumors compared to adjacent
stroma was also observed. Genetically engineered mouse models of spontaneous pancreatic ductal
adenocarcinoma were used to investigate APLP20 s role in cancer development. We found that APLP2
expression intensifies significantly during pancreatic cancer initiation and progression in the LSLKrasG12D/+ ; LSL-Trp53R172H/+ ; Pdx-1-Cre (KPC) mouse model, as shown by immunohistochemistry
analysis. In studies utilizing pancreas-specific heterozygous and homozygous knockout of APLP2
in the KPC mouse model background, we observed significantly prolonged survival and reduced
metastatic progression of pancreatic cancer. These results demonstrate the importance of APLP2 in
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pancreatic cancer initiation and metastasis and indicate that APLP2 should be considered a potential
therapeutic target for this disease.
Keywords: amyloid precursor-like protein 2; mouse model; pancreatic cancer

1. Introduction
Pancreatic cancer is one of the leading causes of cancer-related deaths in the United
States, and patients with this illness face a dismally low 5-year survival rate [1]. More indepth understanding of pancreatic cancer progression and the development of efficacious,
targeted strategies are necessary. Amyloid precursor-like protein 2 (APLP2), a type 1
transmembrane glycoprotein, is a member of the amyloid precursor protein family, and it is
expressed throughout the body at varying levels [2–4]. Previous work from our laboratory
and other research groups has shown that APLP2 is increased in expression in a variety
of human cancers, including Ewing sarcoma, breast cancer, and pancreatic cancer [5–10].
Results from our laboratory demonstrated that the transfection of pancreatic cancer cells
in vitro with APLP2 short interfering RNA (siRNA) reduced their growth, and transfection
with either APLP2 short hairpin RNA (shRNA) or siRNA reduced their migration [6,10].
Our previous studies also showed that knockdown of APLP2 by APLP2-specific shRNA
significantly inhibited xenograft pancreatic tumor growth and reduced metastasis to the
intestine, diaphragm, and kidney in athymic nude mice [10]. These published findings
support a role for APLP2 in pancreatic cancer pathogenesis and also raise the question of
whether APLP2 contributes to pancreatic cancer development.
Our current findings show an increase in APLP2 expression in human patient pancreatic adenocarcinoma epithelial cells compared to precursor pancreatic intraepithelial
neoplasia (PanIN) lesions (as well as stromal cells), which indicates a correlation between
the level of APLP2 expression and the development of pancreatic cancer. Accordingly, we
also demonstrated that APLP2 is more highly expressed in tumor specimens acquired from
the LSL-KrasG12D/+ ; LSL-Trp53R172H/+ ; Pdx-1-Cre (KPC) mouse model [11,12] than in normal
mouse pancreas tissue. To study the role of APLP2 in pancreatic cancer initiation and
progression, we generated a variant of the KPC model with a conditional, pancreas-specific
knockout of APLP2, thus allowing for longitudinal investigation of the impact of APLP2 on
pancreatic cancer development. Findings from this novel mouse model show a significant
improvement in the survival of KPC mice with pancreas-specific hetero- or homozygous
knockout of APLP2. Overall, our findings demonstrate the contribution of APLP2 as a
potentiating factor in pancreatic cancer development and progression, and thus support
future studies to evaluate APLP2 as a preventative or therapeutic target.
2. Results
2.1. APLP2 mRNA Expression Is Higher in Human Primary Pancreatic Tumors Relative to PanIN
Epithelial and Stromal Cells
We investigated the expression of APLP2 in human patient samples of pancreatic
adenocarcinoma using RNA-Seq technology [13,14]. Relevant data from the analysis of
the expression patterns of marker genes that we used for epithelial cells and stromal cells
in our set of human tissue samples have been shown in a previous report published by
some members of our research group [13]. As was noted in this publication, the marker
genes for epithelium were KRT19, EPCAM, and CDH1. For stroma, the marker genes used
were VWF, ENG, and CDH5 (for endothelial cells), DCN, ACTA2, and FAP (for cancerassociated fibroblasts), and PTPRC, CD4, and CD163 (for leukocytes) [13]. As displayed
in Figure 1 and Table 1, human primary tumor epithelial cells have increased expression
of APLP2 compared to human PanIN epithelial cells, indicating a rise in APLP2 as the
lesion progressed from PanIN to a tumor (Table S1 lists the data for all the individual
RNA-Seq values from which the mean values shown in Table 1 were derived). In addition,
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we observed higher APLP2 expression in epithelial cell samples compared to stromal
cell samples. These data complement our earlier reports that showed APLP2 protein
expression is elevated in human pancreatic primary tumors and metastases in relation to
normal pancreas tissue [8,10].

Figure 1. Human primary tumor epithelial cells highly express amyloid precursor-like protein 2 (APLP2). By RNA-Seq
analysis, human primary tumor epithelial cells were demonstrated to express significantly more APLP2 than human
pancreatic intraepithelial neoplasia (PanIN) epithelial or stromal cells. TPM = Transcripts Per Million.
Table 1. Differential APLP2 gene expression analysis.
Group 1

Group 2

Mean
Group 1

Mean
Group 2

logFC *

t-Statistic

FDR **

PanIN Epi ***

PanIN Stroma

9.82

9.10

−0.719

−5.37

8.87 × 10−6

PDA Epi ****

PDA Stroma

10.45

8.89

−1.560

−18.80

4.71 × 10−52

PanIn Epi

PDA Epi

9.82

10.45

0.637

3.84

1.58 × 10−03

PanIN Stroma

PDA Stroma

9.10

8.89

−0.211

−1.78

2.46 × 10−1

All Epi

All Stroma

10.39

8.93

−1.460

−19.40

6.54 × 10−57

* Positive log fold changes (logFC) indicate higher levels in Group 2, and negative logFC indicates lower levels; ** FDR = False Discovery
Rate; *** PanIN Epithelial Cells; **** Pancreatic Ductal Adenocarcinoma Epithelial Cells.

2.2. Murine KPC Primary Pancreatic Tumor Tissue Has Increased Expression of APLP2 Protein
Compared to PanINs
By immunohistochemistry, we also analyzed the expression of murine APLP2 in
normal and pancreatic adenocarcinoma tissues acquired from KPC mice (Figure 2). Minimal
to no expression of APLP2 was observed in normal pancreas tissue (n = 6). However, we
saw significant increases in APLP2 staining during disease progression (n = 7) relative
to the normal pancreas. Further classification of the tissues into developmental stages of
the disease (PanIN 1, PanIN 2, PanIN 3, low-grade carcinoma, and high-grade carcinoma)
revealed weak to moderate staining in PanIN 1 lesions (with 60–70% of the cells displaying
immunoreactivity). PanIN 2 lesions exhibited moderate staining for APLP2, while PanIN 3
and pancreatic adenocarcinoma samples showed strong staining of APLP2 with ~90–100%
of cells positively stained (particularly ductal epithelial cells). Overall, we have found that
APLP2 protein expression increases as pancreatic cancer develops in KPC mice.
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Figure 2. APLP2 increases with progression to pancreatic adenocarcinoma in a mouse model. Immunohistochemistry was
used to analyze the expression of APLP2 in tissue samples from 20-week-old KPC mice. (A) APLP2 staining was absent in
normal pancreas tissues. PanIN 1, 2, and 3 displayed weak to strong staining of APLP2 in the cytoplasm. Both low- and
high-grade pancreatic cancer samples with intensely positive cytoplasmic APLP2 staining >80% are shown. A scale bar is
displayed in the lower right corner of each section. For all sections except the bottom middle one, the scale bar represents
50 µm. For the bottom middle section, the scale bar represents 100 µm. (B) The expression of murine APLP2 in normal and
pancreatic tissue is graphically represented in a box plot, which shows the immunohistochemistry data based on H-scores.
These scores indicate a statistically significant increase in APLP2 expression in murine PanIN 1 (* p < 0.05) compared to the
normal murine pancreas and in PanIN 2 compared to PanIN 1 (** p < 0.01). APLP2 expression was significantly greater
in PanIN 3/pancreatic cancer relative to the normal pancreas (* p < 0.05). NS = Not Significant. The staining was scored
according to intensity on a 0–3 scale (0 = negative, 1 = weak, 2 = moderate, 3 = strong). The percentage of cells stained for
murine APLP2 was evaluated based on the absolute stain (i.e., 10–100% is scored as 0.1 to 1). The Histo-score (H-score) was
calculated by multiplying the staining intensity by the percentage of cells positive for APLP2 expression. Statistical analysis
was performed using the Student’s t-test.
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2.3. Loss of APLP2 Specifically in the Pancreas Prolongs the Survival of KPC Mice
To gain a deeper understanding of the role of APLP2 in pancreatic cancer development,
we generated a new variant of the KPC mouse model that had APLP2 deficiency in the
pancreas. To begin, a strain with conditional potential for mouse Aplp2 gene deletion
(the Aplp2tm1a/tm1a strain) was crossed with the FLPo-10 mouse strain (which expresses
FLP recombinase) to generate Aplp2tm1c/+ animals. The Aplp2tm1c/+ (and Aplp2tm1c/tm1c mice
generated from their interbreeding) are able to grow and reproduce normally, and they
have no apparent abnormal phenotypic or developmental characteristics. To produce
quadruple mutant animals, LSL-Aplp2tmi1c/tm1c mice were crossed with LSL-KrasG12D/+ ;
LSL-Trp53R172H/+ mice, followed by the crossing of LSL-KrasG12D/+ ; LSL-Trp53R172H/+ ; LSLAplp2tmi1c/tm1c mice with Pdx-1-Cre mice.
APLP2 protein expression in pancreas tissues from quadruple mutant mice was monitored by immunoblotting of tissue lysates obtained from genotyped KPC mice with floxed
Aplp2 (fl/fl), wild-type Aplp2 (+/+), heterozygous Aplp2 deletion (−/+), or homozygous
Aplp2 deletion (−/−), using an antibody specific for a sequence in the C-terminal region of
APLP2 (Figure 3A and Figure S1). APLP2 normally undergoes secretase cleavage within
cells [9], and thus the expression of APLP2 can be confirmed by the detection of an APLP2
cleavage fragment. The expression of APLP2 protein was highest in the floxed and wildtype pancreas tissues (Figure 3A). APLP2 expression was lower in the pancreas tissue
from heterozygous pancreas-specific Aplp2 knockout (−/+), and little to no APLP2 protein
was detectable in the pancreas of the homozygous knockout (−/−). Thus, the decrease in
APLP2 expression was further potentiated by the loss of the second allele, as observed by
the comparison of the immunoblotting results from the heterozygous and homozygous
knockouts (Figure 3A).

Figure 3. Novel variants of KPC mice with pancreas-specific APLP2 heterozygous or homozygous loss exhibited prolonged
survival. (A) Expression of APLP2 in pancreatic tissue samples from mouse strains. Immunoblotting to detect HSC70
as a control (~70 kD), as well as the APLP2 C-terminus (~22 kD), was performed on pancreas tissue lysates from KPC
mice with floxed (fl/fl), wild-type (+/+), heterozygous deletion (−/+), or homozygous deletion (−/−) of APLP2. The
densitometry readings and intensity ratios for these bands are shown in Table S2. (B) Pancreas-specific loss of APLP2
prolongs the survival of KPC mice. The graph displays cumulative survival time in weeks with Week 0 indicating birth. The
mice were monitored at least 3 times weekly and euthanized per Institutional Animal Care and Use Committee (IACUC)
guidelines. Mean survival time +/− standard error of the mean was determined for each group.

The KPC mice with homozygous or heterozygous pancreas-specific knockout of
APLP2, along with KPC (APLP2 wild-type) mice, were monitored for signs of health or
disease (ability to eat and drink, mobility, appearance, palpable tumors or ascites, and
duration of survival). Loss or deficiency of APLP2 in the pancreas did not hinder viability,
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fertility, development, or behavior. When assessing the survival distributions (by KaplanMeier survival analysis), we observed a significant improvement in the mean survival
time of the KPC mice without pancreas APLP2 expression (Figure 3B). Diminished, but
not absent, APLP2 expression in the pancreas (in the heterozygotes) also resulted in a
similar significant lengthening of the mean survival time, relative to the KPC mice that
have wild-type APLP2 expressed in the pancreas (Figure 3B). The KPC-Aplp2+/+ mouse
cohort’s mean survival was 20.8 weeks ± 1.2, compared to a mean survival of 30.7 weeks
± 2.9 for KPC-Panc-Aplp2+/− mice and 31.0 weeks ± 2.8 for KPC-Panc-Aplp2−/− mice.
We noted a significant decrease in metastases in the KPC mice lacking APLP2 expression in the pancreas (Figure 4). At necropsy, the percentages of mice with visible
lung, diaphragm, and peritoneum metastases were significantly lower among the mice
with homozygous, pancreas-specific APLP2 knockout on the KPC background, relative to
KPC (wild-type APLP2) mice. Furthermore, among the mice with heterozygous, pancreasspecific APLP2 knockout on the KPC background, there was a significantly lower percentage with visible metastases to the diaphragm compared to KPC (wild-type) APLP2 mice.
These data indicate that APLP2 strongly influences the extent of metastasis in the KPC
pancreatic cancer mouse model.

Figure 4. Metastatic pancreatic tumor spread was decreased upon homozygous and (to a lesser extent) heterozygous loss
of APLP2 in the background of KPC. At necropsy, the liver, lung, diaphragm, and peritoneum were assessed. Mice with
homozygous loss of APLP2 in the pancreas had significantly fewer metastases to the lung (p = 0.029), diaphragm (p = 0.015),
and peritoneum (p = 0.045) than wild-type mice. Two-way ANOVA and Tukey’s multiple comparisons test were used to
compare the overall metastatic spread between groups. Fisher’s Exact Test with Bonferroni Method Adjustment was used
to compare specific metastatic sites between groups.

3. Discussion
Our work in this study has confirmed APLP2 as a highly expressed regulator of pancreatic cancer, expanding upon past research from our laboratory that indicated APLP2 has
an important role in this disease [6,9,10]. Our published immunoblotting studies indicated
elevated APLP2 expression in human pancreatic cancer cells, and by immunohistochemistry we had demonstrated increased APLP2 presence in primary human pancreatic tumors
and metastases relative to the normal pancreas [6,10]. To obtain a comparison between the
advanced and early developmental stages of pancreatic cancer, we have now also analyzed
RNA-seq data from human pancreatic ductal adenocarcinoma patients and found elevated
expression of APLP2 in human primary tumor epithelium when compared to either PanIN
lesions or stromal cells (Figure 1, Table 1). The additional comparison of mRNA expression
of pancreatic cancer tissue to healthy pancreatic tissue was not made, for the following
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reason. Approximately 90% of the cells in normal pancreas tissue are acinar cells, and
about 90% of the mRNA transcripts in an acinar cell are from digestive pro-enzyme genes.
Therefore, comparing pancreatic ductal adenocarcinoma epithelial cells to normal pancreas
tissues is confounded by the extreme specialization of the vast majority of the cells in
the pancreas. The use of PanINs, instead of normal pancreas tissue, as a control allows
comparison to corresponding cells that are clearly committed to the pre-neoplastic lineage
and yet have extremely low malignant potential. The PanIN control is more biologically
meaningful than normal pancreas tissue would be as a control because it highlights the
changes in expression that arise during the initial development of the tumor, rather than
from dedifferentiation from a highly specialized secretory cell type. The results from our
RNA-seq analysis support the concept of increased APLP2 expression throughout disease
progression in human pancreatic ductal adenocarcinoma.
We had previously shown that inducible knockdown of APLP2 (via shRNA) was
able to delay tumor development, reduce tumor burden, and decrease metastases to
the diaphragm, kidney, and intestine in an orthotopic implantation model of pancreatic
cancer [10]. In an effort to further understand APLP20 s influence on pancreatic cancer
development, we have turned to autochthonous mouse models of pancreatic cancer. We
performed immunohistochemistry analysis on murine KPC pancreas tissue, comparing
normal tissue, early PanIN lesions, and PanIN 3/invasive carcinoma, and revealed higher
expression in PanIN lesions and PanIN 3/carcinoma than in normal tissue (Figure 2).
To be able to gauge the impact of APLP20 s presence in the pancreas on the progression of pancreatic cancer, we also employed in this current study a KPC mouse model
with/without expression of the Aplp2 gene in the pancreas (i.e., conditional, pancreasspecific knockdown of APLP2). We selected the conditional KPC model to use as the basis
for generating this variant as the KPC model allows for the spontaneous formation of PanIN
lesions and the progression of tumors, which mimics the histopathological progression
of human pancreatic cancer. Previous mouse models centered on APLP2 have shown its
contribution to neurological development and processes, and knockout of APLP2 in combination with deficiencies in either APP or APLP1 (the other members of the same protein
family) has been shown to be lethal [15,16]. For the generation of the KPC variant for this
study, we acquired a mouse strain with conditional potential for APLP2 knockdown, and
the breeding of this strain with an FLP recombinase produced a pseudo-wild-type mouse
by removing the lacZ/neomycin promoter cassette. The progeny are considered “floxed” as
they have a loxP-flanked fourth exon. Subsequent breeding of the floxed mice with a Cre
recombinase led to the excision of exon 4, which resulted in the loss of APLP2 expression,
as confirmed via immunoblotting of pancreas tissue lysates (Figure 3A).
Upon generating the conditional KPC mice with pancreas-specific APLP2 loss or
deficiency (i.e., either homozygous or heterozygous knockout of APLP2), we were able to
show prolonged survival in comparison to the KPC mice with wild-type APLP2 (Figure 3B).
At the time that the mice were euthanized due to morbidity (according to our IACUC
protocol), there were no gross differences observed at necropsy in the sizes of the primary
tumors in the KPC Aplp2−/− , KPC Aplp2−/+ , and KPC Aplp2+/+ mice. Thus, pancreasspecific complete or partial loss of APLP2 did not entirely prevent tumor growth, although
survival was prolonged by pancreas APLP2 deficiency. We observed bowel and/or biliary
blockages in some of the KPC mice with all three APLP2 genotypes, which is common
within the KPC model. During necropsies, we noted that all three strains of mice had large
primary tumors causing pressure on the intestines and other internal organs, which in
some cases resulted in rectal, urethral, or vaginal prolapses. The fact that it took longer
for the KPC Aplp2−/+ and KPC Aplp2−/− mice to reach the same point of morbidity (and
be euthanized) as the KPC Aplp2+/+ mice suggests that the primary tumors were likely
growing more rapidly in the KPC Aplp2+/+ mice.
A significant decrease in metastases to the lung, diaphragm, and peritoneum was
observed for KPC Aplp2−/− mice compared to KPC Aplp2+/+ mice (Figure 4). KPC Aplp2−/+
mice also had the inhibition of metastatic spread to the diaphragm (relative to Aplp2+/+
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mice). Although the percentage of mice with visible metastases to the liver trended lower
for KPC Aplp2−/− compared to KPC Aplp2−/+ mice, and for KPC Aplp2−/+ compared to
KPC Aplp2+/+ mice, these differences were not statistically significant. There were also no
statistically significant differences in the percentages of mice with visible metastases in
the lung, diaphragm, or peritoneum when KPC Aplp2−/− mice were compared with KPC
Aplp2−/+ mice.
Our data from human samples and mouse models point to the importance of APLP2 in
cancer and signify the importance of APLP2 as a pro-tumor factor in pancreatic adenocarcinoma development. Notably, the survival of mice with either homozygous or heterozygous
knockout of pancreas APLP2 on the KPC background led to similar extensions in survival.
This observation indicates that even partial interference with APLP2 expression and/or
function could potentially have significant therapeutic benefit in future clinical studies.
These results suggest that there is a threshold level of APLP2 in the KPC mouse pancreas
that facilitates tumor pathogenicity, and falling below that threshold to only half that
level (i.e., to the heterozygous level) impairs APLP20 s ability to exercise its pro-tumor
effects. One of the precedents for our observation that heterozygous and homozygous
gene deletion leads to similar cancer phenotypes is a study in the prostate cancer field [17].
Hafeez et al. reported that either heterozygous or homozygous deletion of protein kinase
C epsilon (PKCε) was capable of reducing the development and metastasis of prostate
cancer in the FVB/N TRAMP mouse model [17]. Tumor weights for the heterozygous and
homozygous knockout mice were significantly different from the TRAMP mice, but not
from each other [17]. Therefore, partial loss of the expression of another protein (i.e., PKCε)
was also able to impact phenotype in a mouse tumor model to a similar extent as full loss,
as we have seen with APLP2. Our results with the novel KPC Aplp2−/− , KPC Aplp2−/+ ,
and KPC Aplp2+/+ mouse strains will promote the pursuit of additional studies to validate
APLP2 as a target for utilization in new efforts to treat pancreatic cancer.
4. Materials and Methods
4.1. RNA-Seq
The process used for gene expression analysis of human pancreatic tumor epithelial
cells and stromal cells has been reported [13,14]. Frozen pancreatic adenocarcinoma tissue
samples that had intact RNA were selected. Prior to sample processing, target lesions
were verified by a pathologist specializing in gastrointestinal cancers. The tissues were
then microdissected, and cell type-specific markers were used to confirm the complete
separation of epithelial and stromal samples. A total of 229 epithelial samples were
analyzed: 203 from primary tumors and 26 from low-grade PanINs. The number of stromal
samples assessed was 125 (each with matched epithelium), including 102 from primary
tumors and 23 from low-grade PanIN samples. Paired samples of isolated epithelial cells
and stromal cells were prepared for each patient (>1000 cells/sample). Libraries were
generated using the Ovation RNA-Seq System V2 Kit (NuGEN, San Carlos, CA, USA), and
the cDNAs were sequenced with a HiSeq 2000 (Illumina, San Diego, CA, USA) (3500 to
30,000,000 100-base-pair single-end reads). The y-axis shows log2 Transcripts Per Million
(TPM), calculated by dividing the read counts for APLP2 by the length of the APLP2 genetic
sequence in kb, and then dividing by a scaling factor (total reads per kb for all genes in the
dataset/1,000,000). The TPM unit allows comparison of the proportion of reads mapping
to a particular gene between samples. APLP2 was detected with ≥1 TPM in all samples.
4.2. Mice Breeding and Genotyping
The novel mouse crosses described in this report were performed according to the University of Nebraska Medical Center IACUC and U.S. Public Health Service guidelines, as
well as the guidelines of the International Council for Laboratory Animal Science (ICLAS).
In this project, the mice were treated in a humane manner, and in all instances, pain and discomfort to the mice were kept minimized. The mouse strain with conditional potential for
APLP2 deletion (the C57BL/6N-Atm1BRD APLP2tm2a(EUCOMM)Hmgu /BayMmucd strain, ab-
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breviated as the APLP2tm1a/tm1a strain) was purchased from the Mutant Mouse Resources
and Research Center (MMRRC) at the University of California-Davis (Davis, CA, USA).
This strain had been made using a knockout-first allele with promoter-driven cassette
(KOMP) strategy (European Conditional Mouse Mutagenesis Program, EUCOMM) [18,19].
The B6.Cg-Tb(Pgk1-flpo)10Sykr/J strain (more commonly known as the FLPo-10 strain)
was obtained from the University of Nebraska Medical Center Mouse Genome Engineering
Core Facility (which had acquired it from Jackson Laboratories, Bar Harbor, ME, USA).
The LSL-KrasG12D/+ , LSL-Trp53R172H/+ , and Pdx-1-Cre strains were gifts from Dr. David
Tuveson (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA), and these strains
were extensively backcrossed to C57BL/6 by the Rachagani and Batra research group.
The process of generating the KPC mice that were APLP2+/+ , APLP2+/− , or APLP2−/−
in the pancreatic cells is shown in Figure 5. In the APLP2 EUCOMM targeting vector, the
promoter-driven cassette, as well as the flippase recognition target (FRT) and loxP (excision) sites, is inserted into the APLP2 gene between exons 3 and 5 (Figure 5A). Initial
crosses were set up between the APLP2tm2a/tm2a strain and the FLPo-10 mouse. This cross
produced a pseudo-wild-type mouse as the FRT-flanked region containing the promoterdriven cassette was excised and recombined by the FLP recombinase. The APLP2tm2a/tm2a x
FLPo-10 progeny are denoted as APLP2tm1c/+ or floxed mice. The APLP2tm1c/+ mice were
backcrossed to produce the homozygous APLP2tm1c/tm1c or floxed/floxed mice. The floxed
mice were then used as the founder line for the generation of knockout mice and also as a
control line for experimental analysis. For consistency in nomenclature, in this report, the
APLP2tm1c/tm1c or floxed/floxed mice are denoted in the same manner as the KPC strains,
i.e., as LSL-APLP2tm1c/tm1c or LSL-APLP2tm1c/+ .
Before the generation of quadruple mouse crosses expressing all the genetic components of the KPC mouse and pancreas-specific deficiency of APLP2, we first confirmed that
crosses expressing Pdx-1-Cre (a construct encoding the Cre recombinase protein specifically
in pancreatic cell lineages) and the floxed tm1c construct would have the expected loss of
the Aplp2 gene exon 4 sequence (Figure 5A). As shown in Figure 5B(i), Pdx-1-Cre;Aplp2fl/fl ,
Pdx-1-Cre;Aplp2fl/+ , and Pdx-1-Cre;Aplp2+/+ mice did indeed have the anticipated genetic
outcomes, as revealed by detection of polymerase chain reaction (PCR) products of the
appropriate sizes upon genotyping. Likewise, we verified that Pdx-1-Cre;KrasG12D/+ and
Pdx-1-Cre;Kras+/+ mice (Figure 5B(ii)), Pdx-1-Cre;Trp53R172H/+ and Pdx-1-Cre;Trp53+/+ mice
(Figure 5B(iii)) and Pdx-1-Cre+/+ and Pdx-1-Cre−/− mice (Figure 5B(iv)) all exhibited the
expected PCR genotyping results in preliminary testing.
Next, to produce quadruple mutant animals, LSL-Aplp2 tmi1c/tm1c mice were crossed
with LSL-KrasG12D/+ ;LSL-Trp53R172H/+ mice, followed by a crossing of LSL-KrasG12D/+ ;LSLTrp53R172H/+ ;LSL-Aplp2tmi1c/tm1c mice with Pdx-1-Cre mice (Figure 5C). Thus, the LSLAPLP2tm1c/tm1c or LSL-APLP2tm1c/+ mice (which have conditional potential) were interbred
with the conditional LSL-KrasG12D/+ LSL-Trp53R172H/+ mice. Finally, the LSL-KrasG12D/+ LSLTrp53R172H/+ LSL-APLP2tm1c/+ mice or the LSL-KrasG12D/+ LSL-Trp53R172H/+ LSL-APLP2tm1c/tm1c
mice were crossed with the Pdx-1-Cre strain, yielding novel mutants with either homozygous or heterozygous APLP2 loss. The progeny of such crosses are identified
as LSL-KrasG12D/+ LSL-Trp53R172H/+ LSL-APLP2tm1d/+ Pdx-1-Cre or as LSL-KrasG12D/+ LSLTrp53R172H/+ LSL- APLP2tm1d/tm1d Pdx-1-Cre animals on a C57BL/6J background.
For mouse genotyping, proteinase K in a lysis buffer consisting of 100 mM Tris (pH 8.8),
5 mM ethylenediaminetetraacetic acid (EDTA), 0.2% sodium dodecyl sulfate (SDS), and
200 mM NaCl (Fisher Scientific, Hampton, NH, USA) in H2 O was used to extract DNA
from a small portion (<5 mm) of each tail clipping that was collected from mouse pups
14–21 days of age. PCR amplification was performed using GoTaq Master Mix (Promega,
Madison, WI, USA) with a set of primers for each gene of interest (Kras, p53, Pdx-1-Cre, and
APLP2).
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Figure 5. Generation of KPC variants with APLP2 deficiency in the pancreas. (A) The initially
engineered mouse Aplp2 construct (called tm1a) has FRT sites (blue triangles) flanking the lacZ/neo
promoter cassette. Crossing mice expressing tm1a (Aplp2tm1a/tm1a ) with Flp recombinase-expressing
mice (FLPo10) produced mice expressing the tm1c construct, which lacks the lacZ/neo promoter
cassette that had been flanked by FRT sites and which has a loxP-flanked fourth exon (thus, mice
expressing tm1c are also referred to in this report as floxed LSL-Aplp2 mice). Subsequent breeding with
Cre recombinase-expressing mice (Pdx-1-Cre) removed the fourth exon of the Aplp2 gene. (B) The mice
strains were genotyped by PCR. (i) Co-expression of Pdx-1-Cre with Aplp2fl/fl , Aplp2fl/+ , or Aplp2+/+
results in differential PCR products. (ii, iii, iv) PCR amplification of conditional mutant (floxed)
alleles resulted in a PCR product of ~600 bp for LSL-KrasG12D/+ and ~250 bp for LSL-Trp53R172H/+ .
For Pdx-1-Cre, the genotyping PCR amplification resulted in a product of ~600 bp. (C) The stepwise
mouse breeding strategy is shown.
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The PCR primer sequences were acquired from Eurofins Scientific (Luxembourg,
Luxembourg), and their sequences are shown in Table 2. The PCR products were run on
2% agarose (VWR, Radnor, PA, USA) gels with GreenView Plus Gel Stain (GeneCopoeia,
Rockville, MD, USA) in 1× Tris-acetate-ethylenediaminetetraacetic acid (EDTA) (TAE)
buffer. The 1× TAE buffer is composed of 40 mM Tris, 20 mM acetic acid, and 1 mM EDTA.
The gels were imaged using a Bio-Rad Gel Doc (Hercules, CA, USA).
Table 2. PCR primer sequences for genotyping.
Gene

Primer Sequence

K-ras

50 -GTCGACAAGCTCATGCGGGTG-30

K-ras

50 -CCTTTACAAGCGCACGCAGACTGTAGA-30

K-ras

50 -AGCTAGCCACCATGGCTTGAGTAAGTCTGCA-30

Trp53

50 -CTTGGAGACATAGCCACACTG-30

Trp53

50 -AGCTAGCCACCATGGCTTGAGTAAGTCTGCA-30

Trp53

50 -TTACACATCCAGCCTCTGTGG-30

Pdx-1-Cre

50 -CTGGACTACAATCTTGAGTTGC-30

Pdx-1-Cre

50 -GGTGTACGGTCAGTAAATTTG-30

APLP2

50 -ACATTTCCTGGCTACAATCCTGTGC-30

APLP2

50 -ATTATTAGACTTGGCAGGCATGCTG-30

4.3. Immunohistochemistry
Tissue specimens were collected from 20-week-old KPC mice (n = 13 total specimens,
n = 6 normal pancreas specimens and n = 7 pancreatic tumors) and fixed in 10% neutral
buffered formalin for 72 h at room temperature prior to embedding in paraffin (Fisher
Scientific, Hampton, NH, USA). The immunohistochemical staining and analysis were
performed as per a published protocol [20]. In brief, the slides were deparaffinized using
xylene followed by rehydration in a series of 10-min incubations in alcohol solutions
ranging from 100% to 20%. The tissues were immersed in 3% H2 02 in methanol to block
endogenous peroxidase activity prior to antigen retrieval which involved incubation with
0.01 M citrate buffer (pH 6.8). The ImmPRESS Polymer Detection kit (Vector Laboratories,
Inc., Burlingame, CA, USA) was used as a blocking agent for 2 h at room temperature
before the sections were incubated with the primary antibody in 1% bovine serum albumin
(BSA), 0.5% Tween in Tris-buffered saline (pH 7.3) at 4 ◦ C for 24 h in a humidity chamber.
The tissues were washed and then incubated with peroxidase-labeled secondary antibody
(universal anti-mouse/rabbit immunoglobulin G antibody) for 30 min at room temperature.
The immunostaining was completed by using a peroxidase substrate detection kit (Vector
Laboratories, Inc.). The stained slides were scored, and representative pictures were taken
and analyzed. Staining intensity was evaluated as follows: negative staining = 0, weak
staining = 1, moderate staining = 2, and strong or intense staining = 3. A composite score
was calculated as the percentage of positive cells multiplied by the intensity of staining.
4.4. Tissue Collection, Protein Quantification, and Immunoblotting
Mouse pancreatic tissue was collected, washed once with cold PBS, and then flashfrozen in liquid nitrogen. Cell lysis buffer was added to the tissue before processing with a
mortar and pestle. The cell lysis buffer was composed of the following reagents from Sigma
(St. Louis, MO, USA): 1 mM ethyleneglycol-bis(β-aminoethyl)-N,N,N0 ,N0 -tetraacetic acid,
1 mM EDTA, 50 mM Tris-HCl pH 7.5, 1% Triton X-100, 2 mM dithiothreitol and 0.1 mM
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phenylmethylsulfonyl fluoride in addition to 1 mM Na3 VO4 and 1 µg/mL Halt Cocktail
from Thermo Fisher Scientific (Waltham, MA, USA) Following harvest, the lysates were
stored at −80 ◦ C overnight, then thawed on ice, and centrifuged in an Eppendorf 5810R
centrifuge at 13,000 rpm for 30 min at 4 ◦ C. The supernatants were transferred to new tubes
and stored at −80 ◦ C until use. All samples underwent protein quantification using the
Pierce BCA Protein Assay Kit per the manufacturer’s protocol (Thermo Fisher Scientific).
Aliquots of the lysate supernatants were mixed with 5× sodium dodecyl sulfate loading
dye (250 mM Tris-HCl pH 6.8, 10% w/v sodium dodecyl sulfate (Tokyo Chemical Industry
Company, Portland, OR, USA), 30% v/v glycerol (Sigma), 5% v/v β-mercaptoethanol
(Sigma), 0.02% w/v bromophenol blue (Sigma)) and heated for 5 min at 95 ◦ C prior to
loading. The samples were loaded on 4–20% or 10–20% Invitrogen Novex Tris-glycine
polyacrylamide pre-cast gels (Thermo Fisher Scientific). Electrophoresis was performed at
90 V at room temperature followed by protein transfer at 50 V for 2.5 h at room temperature
to polyvinylidene difluoride Immobilon-P Millipore membranes. The membranes were
blocked for 1 h in a 5% w/v solution of nonfat dry milk prior to incubation overnight
at 4 ◦ C with primary antibodies. Next, the membranes were washed 3 times with 1%
Tween-20 (Thermo Fisher Scientific) in PBS for 5 min. The membranes were incubated with
secondary antibodies for 1 h at room temperature before being washed 3 times for 5 min
with 1% Tween-20 in PBS. The proteins were then visualized, which involved incubating
the membranes in Pierce ECL Western Blotting Substrate (Thermo Fisher Scientific 32106),
and imaged using the ChemiDoc MP (Bio-Rad, Hercules, CA, USA). Densitometry was
performed using ImageJ.JS (ImageJ compiled into Javascript and integrated with ImJoy),
freely available at https://ij.imjoy.io (accessed on 17 March 2021).
4.5. Statistical Analysis
Mouse survival distributions were assessed via Kaplan–Meier plots and log-rank test.
Reaching a tumor volume of 1000 mm3 or a time period of 54 days post-treatment initiation
was each designated as an experimental endpoint, and mice alive at the completion of the
study were treated as censored. The log-rank test allowed for the comparison of survival
distributions among groups.
Two-way ANOVA and Tukey’s multiple comparisons analysis were performed in
GraphPad Prism Version 8 (GraphPad Software, San Diego, CA, USA) and were used to
compare the overall metastatic spread among groups. Fisher’s Exact Test with Bonferroni
Method Adjustment was used to compare individual metastatic sites among groups.
5. Conclusions
The comprehension of APLP20 s roles in migration and growth has been expanding,
based on a mounting number of studies [6,9,10,21–32]. Our findings from this novel KPC
APLP2 mouse model show a significant improvement in the survival of KPC mice with
pancreas-specific, heterozygous or homozygous knockout of APLP2. The establishment of
these novel mouse strains will provide numerous avenues of investigation for defining the
functions of APLP2 in the development and progression of pancreatic cancer.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/cancers13071535/s1, Figure S1: Original immunoblot corresponding to Figure 3A, Table S1:
APLP2 Expression Values for Each Sample, Table S2: Densitometry Readings and Intensity Ratios for
Figure S1 and Figure 3A.
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